Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Reduction of risk of NSAID-associated gastric ulcers in patients at risk.
* Pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily. For some patients, 20 mg orally once daily may be sufficient.
* **NSAID-associated gastric ulcers:** 40 mg orally once daily. For patients requiring continued NSAID use, treatment can be continued for up to 6 months.
* **Zollinger-Ellison syndrome:** Initially 40 mg orally or intravenously once daily. Doses may be adjusted based on clinical response. Doses up to 240 mg daily have been administered intravenously, divided into 2 doses. Oral doses up to 240 mg daily have been administered, divided into 2 doses.
## Pediatric Dosing
* **Children 5 to 16 years:**
* **Erosive esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily.
* Dosing for children under 5 years has not been established by the FDA.
## Dose Adjustments
* **Hepatic impairment:** Maximum dose of 40 mg orally once daily.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of its formulation.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, rash.
* **Long-term use may be associated with:**
* Fractures of the hip, wrist, or spine (increased risk).
* Clostridium difficile-associated diarrhea.
* Vitamin B12 deficiency.
* Hypomagnesemia (can be severe and may require magnesium supplementation).
* Systemic lupus erythematosus (new onset or exacerbation).
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Antiretrovirals (e.g., rilpivirine, atazanavir), certain antifungals (e.g., ketoconazole, itraconazole), certain tyrosine kinase inhibitors (e.g., erlotinib). Pantoprazole can decrease absorption.
* **CYP2C19 substrates:** Pantoprazole may increase levels of drugs metabolized by CYP2C19 (e.g., clopidogrel, warfarin, phenytoin).
* **Methotrexate:** PPIs may increase methotrexate levels. Consider holding PPI during methotrexate treatment.
## Monitoring
* Electrolytes (especially magnesium), especially with long-term use or concomitant diuretic use.
* Signs and symptoms of C. difficile infection.
* Bone mineral density in patients at risk for osteoporosis.
* Effectiveness of treatment for GERD or erosive esophagitis.
## Clinical Pearls
* For oral administration, pantoprazole is available as delayed-release tablets. Do not crush or chew the tablets.
* For IV administration, reconstitute and further dilute per manufacturer instructions.
* Acid suppression may increase serum creatinine.
* The risk of bone fractures is higher with higher doses and longer duration of use.
***
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and local protocols for complete and up-to-date guidance.*
